Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes
Posted: 31 May 2013 | | No comments yet
Novo Nordisk announced the submission to the EMA of the MAA for the approval of IDegLira…
Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes.
